Skip to navigation Skip to content

Severe facial lipoatrophy Program in Pharmaceutical Benefits Scheme (PBS) 012-18051129

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised polylactic acid (PLA) for patients with HIV associated severe facial lipoatrophy.

Severe facial lipoatrophy and listing dates

Severe facial lipoatrophy is a rare condition described by the disappearance of facial subcutaneous fat. PLA is an injectable liquid used to add volume to areas of the face to create a soft, natural, more youthful re-contouring of the face from severe facial lipoatrophy caused by therapy for HIV infection only. It builds the body's own collagen while it gradually disappears.

Listing date: polylactic acid - 1 September 2009.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to Complex Drugs Programs and choose the team relevant to the condition being treated.

The Resources page contains:

  • contact details
  • restriction and item codes
  • FAQs from Service Officers
  • the PBS schedule

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs